Advertising


News

MS-2 Step gets TGA green light for missed miscarriage


Karen Burge


22/10/2026 3:08:44 PM

It’s one of two major changes to a commonly used abortion medication, alongside new approval to end a pregnancy up to 70 days of gestation, a one-week extension.

A woman having a pregnancy ultrasound.
‘This signals the availability of more comprehensive women’s healthcare in the general practice setting.’

GPs can now offer patients greater access to medical abortion and more options for miscarriage care after the Therapeutic Goods Administration (TGA) approved two major changes to a commonly used abortion medication.
 
MS-2 Step (mifepristone and misoprostol) is now approved for medical abortion up to 70 days’ gestation, extending the previous approved use by seven days, as well as being newly indicated to medically manage missed miscarriage up to 70 days of gestation.
 
For missed miscarriage, where the embryo or foetus has died but the pregnancy tissue remains inside the uterus and has not yet been passed from the body, the TGA says gestational age is determined by ultrasound.
 
In both new approvals, safety data did not reveal any concerns and reported side effects were consistent with the known effects of MS-2.
 
Monash University General Practice Chair and women’s health expert, Professor Danielle Mazza, described the move as ‘highly significant’ for Australian women and GPs.
 
‘These changes bring the approved use of MS-2 Step into line with national clinical guidelines, giving GPs and other healthcare providers greater confidence in the safety and effectiveness of these medications,’ she said.
 
It also ‘signals the availability of more comprehensive women’s healthcare in the general practice setting’, Professor Mazza told newsGP.
 
‘GPs can follow the journey. They can help women to achieve their reproductive goals, and they can take them through contraception, planning pregnancies, dealing with unplanned pregnancies, and now dealing with miscarriage.’
 
For women seeking abortion, this TGA change means ‘they’ve got more time to navigate to care’.
 
‘This is really important because we know that the most disadvantaged women are the ones who have been struggling to get to an abortion provider by nine weeks, so it gives another week, which is great,’ Professor Mazza said.
 
And for those facing a missed miscarriage, she says this new indication provides choice.
 
‘The extension of the indication to missed miscarriage is an important change. This is great for women who, up until now, have had a choice only of expectant management,’ she said.
 
‘They may have had an ultrasound that shows that the pregnancy is not viable, and then they have to wait for the body to expel that pregnancy, and that wait is a very emotional time. Or you have a surgical approach, which is not always desired.
 
‘This gives women another option to take the medication and move forward with the resolution of the miscarriage.’
 
Once only prescribed by certified doctors, MS-2 Step has become more widely available in recent years following a raft of reforms introduced by the TGA in 2023.
 
Professor Mazza said she hopes this latest green light from the TGA will encourage more GPs to consider offering MS-2 Step as a choice to patients under the newly approved indications.
 
‘They’ve got the tick of approval from the TGA to go forward to use these medications and that reassurance is really important to give GPs confidence,’ she said.
 
‘There was no indication [for missed miscarriage] before so while some were doing it off-label, and while it was being used in hospital settings, it probably wasn’t being used in the community, and so now this gives it the green light.
 
‘What I’m hoping is that as GPs start to use this for miscarriage, they’ll gain the confidence also to extend their practice to abortion provision as well, because it’ll take the fear factor out of using these medications as they’ll be more familiar with them.’
 
In communicating its new indications, the TGA outlined research supporting the safety and efficacy of mifepristone and misoprostol that had been provided by the sponsor.
 
According to the TGA, there is ‘strong evidence’ showing mifepristone and misoprostol were effective for the medical termination of pregnancies between 64 and 70 days’ gestation.
 
For example, in one large study, successful termination of pregnancy occurred in 93.5% of women at 57 to 63 days of gestation and 92.8% of women at 64 to 70 days of gestation. Another showed complete termination of pregnancy rates above 93.2% in the 64 to 70 days’ gestation group.
 
‘These results showed that MS-2 Step did not become less effective in the 64 to 70 days of gestation interval when compared to the 57 to 63 days of gestation interval,’ the TGA said.
 
For the medical management of missed miscarriage up to 70 days of gestation, the TGA found published data, clinical guidelines, real-world data, and the known safety profile of mifepristone and misoprostol ‘support the use of MS-2 Step in missed miscarriage up to 70 days of gestation’.
 
An analysis which combined the results of multiple published studies found mifepristone followed by misoprostol was more effective in achieving complete miscarriage than waiting for the miscarriage to complete naturally. This benefit applied to missed miscarriages only, the TGA said.
 
While the changes are now in effect, Pharmaceutical Benefits Scheme subsidies have not yet been extended to cover the newly approved uses.
 
‘It would be logical for that to happen, and I don’t think there’ll be an issue,’ Professor Mazza said.

She added that for GPs who would like further education, support is available through AusCAPPS – the Australian Contraception and Abortion Primary Care Practitioner Support Network.
 
‘We’ll be updating the resources around the extension of these, the indication to 10 weeks and the new indication of miscarriage, and we hope GPs can use it as a go-to site,’ she said.
 
Log in below to join the conversation.


abortion medical abortion mifepristone miscarriage misoprostol MS-2 Step women’s health


newsGP weekly poll In the past five years, have you experienced or observed sexism, misogyny, or gender bias from patients towards female or non-binary GPs?
 
48%
 
2%
 
26%
 
22%
Related



newsGP weekly poll In the past five years, have you experienced or observed sexism, misogyny, or gender bias from patients towards female or non-binary GPs?

Advertising

Advertising

 

Login to comment

Dr Kristy Louise Tybura   23/10/2026 10:35:09 AM

Apart from the extension to 70 days, this sounds more like a clarification than a new indication to me. The previous indication didn't state that the pregnancy had to be viable and it was quite routinely being used for patients who wanted a medical termination and were found to have missed miscarriages on their dating ultrasounds. This just highlights the possibility of it being an option for people with a wanted pregnancy which unfortunately didn't work out.